Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SVFC get em while you can SVFC is not getting any cheaper!!!
SVFC KEEPS GOING UP!!!!
SVFC OMG!!! Just think about all the MONEY SVFC is going to make for longs!!!
SVFC is a once in a lifetime opportunity!!!!
SVFC IS GOING UP!!!!
GREAT !!!! thank you
177k left@ .0038 and then .0044?!!!
NITE SITTING @ .0044
closing in on the 50dma @ .0042!!
SVFC IS A ROCK STAR!!!!
SVFC GOING UP!!!
GREAT NEWS!!!! thanks for sharing! I will be loading more SVFC shares!!! This just keeps getting better!!!
SVFC GOING UP!!!
SVFC is not paying Andrews anything!!!! Until after SVFC closes a capital raise!!! FACT[
quote]and except for twice it always came w/ links & quotes & when not it was so that I would be asked to post it again wink
Quote:
Consulting Agreement
On March 11, 2014, the Company executed a Consulting Agreement (the “ Consulting Agreement ”) with Dr. James Andrews, effective March 7, 2014, pursuant to which Dr. Andrews shall serve as Chairman of the Intellicell Orthopedic Cellular Therapy Advisory Board. The initial term of the Agreement shall be for a period of ten (10) years unless extended as provided in the Agreement or unless terminated by either party with thirty (30) days advance written notice to the other party. In consideration for Consultant’s services, the Consultant shall be paid a monthly fee and make a monthly charitable contribution to the Andrews Foundation after the Company closes a Capital Raise (as defined in the Consulting Agreement), and the amount of such monthly fee and monthly charitable contribution shall be determined based on the amount raised in the Capital Raise. For example, if the value of the Capital Raise is equal to or greater than $2,000,000 but less than $15,000,000, the monthly fee payable to the Consultant thereafter shall be equal to $30,000 (with $6,000 of such amount payable to Dr. Michael Immel) with a charitable contribution of $10,000 payable to the Andrews Foundation thereafter for the term of the Consulting Agreement.
Furthermore, commencing on March 1, 2014 and ending on May 1, 2017, on each of March 1, June 1, October 1 and January 1 during such period, the Company shall issue and the Consultant shall be entitled to receive non-qualified stock options to purchase a number of shares of the Company’s common stock equal to 750,000 divided by the average of the closing bid price per share of such common stock for the ten (10) trading days immediately prior to the date of issuance, subject to certain adjustments as set forth in the Consulting Agreement. The options have a strike price of $0.0058 per share and are exercisable for ten (10) years. A portion (13.33%) of such options will be issued to the Andrews Foundation (and Dr. Immel shall receive 20% of such options). In addition, The Company shall issue to the Consultant 6,666,666 shares of its common stock based on the market price at the date of the execution of the License Agreement (see description above), as well as 2,000,000 shares to Dr. Immel and 1,333,333 shares to the Andrews Foundation. Additionally, 1,000,000 shares shall be issued to the Consultant, 200,000 shares shall be issued to Dr. Immel and 133,333 shares shall be issued to the Andrews Foundation upon FDA approval of the Company’s Stromal Vascular Fraction Cell injection for treatment of osteoarthritis. [/quote]
you have posted this several times over the last week and I have yet to see the link backing up you're statement!
SVFC is going to make short work of the short interests very shortly!!!
.004 break looks very likely! and then tomorrow .0043 and the next day .0047 and break .005 by Friday! that is of course without news. News can send SVFC to penny land in a matter of minutes!!!
SVFC keeps moving up!
Publication in The American Journal of Medicine!!!! Now this is a big deal!!! They don't just let any quack publish in the American Journal of Medicine!!! SVFC is the real deal!!!
SVFC is going up !!!
SVFC is on a roll!!! Anybody noticing a pattern here? Four or five tics up intraday and then two tics down to close. Then the next day we repeat closing at the high of the previous day. This has been the case for five or six days in a row!! This is a great continuation pattern and with the 5, 10 and 15 simple dma crossing this confirms that this reversal is real and should continue for some time!!! Possibly breaking .02 / .03 before consolidating!!
Oh, and don't forget.... Any news will put SVFC on the fast track to multi pennies!!!
SVFC is going to be on fire all summer long!!! I'm betting we break .10 before fall!! Hang on to you're shares we have a winner here!!!!!
SVFC going UP!!!!!
SVFC is on its way back up to its fair pps!!! .03 / .05
We all knew this was going to happen! And now it is final!!! A press release should follow shortly and even tho we knew what the outcome would eventually be it is now FINAL and SVFC should see a nice pop in share price!!! Things are most definitely going in the right direction!!! It's going to get very exciting around here!!!
SVFC Going up!!
Great news!!!!! Ironridge is final!!!
Judge Oing has granted plaintiffs (SVFC ) motion to confirm!!!
It is officially over!!!
https://iapps.courts.state.ny.us/fbem/DocumentDisplayServlet?documentId=HxUqTIxXZ/zNBaERnLoKnQ==&system=prod
ALERT ALERT ALERT
SVFC IS MOVING UP!!!
ALL SHORT INTERESTS SHOULD SEEK COVER IN A STURDY STRUCTURE AND ASSUME THE KISS YOUR A$$ GOOD BY POSITION!!!
here is a sharp pointy SVFC fact....SVFC is moving up!!!
SVFC should see a triple crossover early in the week!!! When this happens I would expect volume and pps to increase dramatically!!! Should be a great week for SVFC longs!!!
Triple Crossover and the Moving Average Ribbon
Additional moving averages may be added to the chart to increase the validity of the signal. Many traders will place the five-, 10-, and 20-day moving averages onto a chart and wait until the five-day average crosses up through the others – this is generally the primary buy sign. Waiting for the10-day average to cross above the 20-day average is often used as confirmation, a tactic that often reduces the number of false signals. Increasing the number of moving averages, as seen in the triple crossover method, is one of the best ways to gauge the strength of a trend and the likelihood that the trend will continue.
http://www.investopedia.com/university/movingaverage/movingaverages4.asp
the wall is falling!! just a little more buying and she will come tumbling down!!!
SVFC GOING UP!!!
Welcome to SVFC!! WOW you got in at a great time!!! HUGE potential with SVFC
GO SVFC!!
Make no mistake about it SVFC is moving UP!!! This steady climb looks like it will continue!! And it is adding up very nicely!!!
starting to chip away at the .0035 wall!!! lets see if we can break it and move to .0038
GO SVFC
SVFC Technology
We use a proprietary, patented technology developed by our founder, Dr. Steven Victor, which provides us with the ability to extract, separate and process the stromal vascular fraction cells from the blood vessels in adult adipose (fat) tissue in about one hour. We believe that our technology produces the most cells from the least amount of fat (60 cc) at the lowest cost and the least amount of manipulation when compared to other technology or processes currently available that employ manipulative processes or enzymes to achieve cell separation. Further, all cells manufactured using our technology and proprietary process are done so under strict United States Food and Drug Administration (“FDA”) cGTP guidelines and SOPs that we have established.
We believe that stromular vascular fraction (“SVFs”) derived from the application of our proprietary process yield a functionally diverse population of cells that are synergistic and able to communicate with each other and with other cells in their local environment. We also believe that since we do not have to wash out the blood and do not digest the extracellular matrix versus competitors’ enzymatic protocols that our product is superior. The mixture of cells has multiple functions and is highly integrated and we believe more potent than adipose stem cells themselves.
We further believe that IntelliCells™, when returned to a patient’s own body by way of same-day same clinical procedure (autologous treatment) and delivered via Point of Care, have little or no risk of disease transfer, rejection or allergic reaction. We also believe that IntelliCells™ have the potential to treat a wide variety of clinical conditions involving orthopedic, gastrointestinal, periodontal, aesthetic and other conditions or disorders.
Our Strategy
We plan to focus our initial efforts on regenerative medicine in the areas of orthopedics, sports medicine, pain, aesthetics and periodontal diseases. According to arthritistoday.org , at least 25 million people nationwide are affected in the world of orthopedics, sports medicine and pain, which, just nationally, makes that a penetrable market into the billions of dollars. Likewise, according to Research and Markets Aesthetics Report and Global Data’s market report for the periodontal market, the aesthetics and periodontal markets make up at least a minimum of $750 million and over a billion dollar market, respectively. We will focus on orthopedics including osteoarthritis, aesthetics, pain, periodontal and other indications by making our Intellicells™ available to practicing physicians using Regen Medical’s office based surgical center (“OBSC”). We plan to establish and install our cGTP cellular processing labs in ambulatory surgery centers and hospitals to make our cellular product available to a wide range of physician specialties to use under the practice of medicine. We believe that we may also be able to license our technology for wound care, cardiac, gastrointestinal (colitis/ileitis), multiple sclerosis and autism to other companies in the regenerative medicine field.
In addition to our core focus noted above in which we provide cGTP cellular processing labs, we also intend to expand our areas of focus, as we are able to locate and partner with parties interested in utilizing or licensing our technology for other areas. In this regard, we intend to engage in a multi-pronged approach with respect to the utilization and commercialization of our proprietary process that will involve entering into technology licensing agreements and related service agreements with physicians and physician practice groups, that we will enable to practice our cell therapy procedures in our US facilities. We will also be seeking to enter into technology licensing agreements or other arrangements that cover particular international territories or countries as described in greater detail below.
Another focus of our business development will involve engaging in and our coordinating Institutional Review Board (”IRB”) approved clinical studies at prominent medical centers, some of which studies may also be the subject of Investigational New Drug applications (“IND’s”) with the goal of obtaining medical or regulatory approval for significant clinical indications, where, if and as required, of the Intellicells™ produced with our proprietary process. We have recently formed a wholly-owned subsidiary, ICBS Research, Inc., through which we plan to engage in research and development activities by collaborating with university based research organizations. We have started our first FDA IND study that will be on osteoarthritis of the knee with Dr. James Andrews and inVentiv as our CRO. We believe these activities may lead to additional patents and intellectual. ICBS Research, Inc., our wholly owned subsidiary, will also coordinate scientific research with world class researchers to learn more about the Intellicell™ process and the use of the cells in medical procedures and as to how it may be used as a more efficacious delivery mechanism or as to how it may be co-administered in conjunction with other medical therapies. In the future Intellicell plans to conduct human clinical studies under an IND in osteoarthritis of the knee, diabetic ulcers of the lower extremities, multiple sclerosis, periodontal gum recession and dermal wrinkles to obtain FDA approval where such approval may be necessary.
We are also exploring and undertaking, either on our own or in collaboration with one or more third parties, providing a service for the collection, processing and storage of autologous cells. We intend to market this service to liposuction patients in addition to any patient who might want to store their SVFs for future use.
Our Competitive Advantage
We believe that our proprietary process offers significant advantages over other competing processes or technologies currently being employed that utilize enzymes or other manipulative methods to harvest or culture cells, including:
We believe that our process is in compliance with existing FDA regulations – under current FDA Guidelines for human cell and tissue based products (HCT/P) (based on FDA regulations found at 21 C.F.R. § 1271), patients are allowed to use their own HCT/P for just about any indication, so long as the use of those cells is autologous (a situation in which the donor and recipient are the same person), the cells are minimally manipulated, the clinical use is homologous, and the procedure takes place as a single procedure as defined by the physician.
Our procedure takes place during the same office visit. The point of care nature of the process is a required element of the protocol required by our licenses, and is emphasized in our technician and physician training.
We believe that the number of adult autologous stem cells and other progenitor cells that comprise the SVF’s that are harvested from the tissue through the use of our proprietary process are significantly higher than the number of cells produced through the use of other technology or processes currently available that employ manipulative processes or enzymes to achieve cell separation.
We had engaged Millipore, a division of Merck, to perform a CD (cluster of differentiation) antibody flow cytometry study which has confirmed the high-quality composition of the IntelliCells™.
We believe that our patented process provides significant time and cost efficiencies at the point of care- using our proprietary ultrasound cavitation technique, SVFs can be separated at low cost and in less time, as compared to competing technologies that utilize enzymes.
http://ih.advfn.com/p.php?pid=nmona&article=62160312
GO SVFC
but.... I bet if you asked him if SVFC is affiliated with Wal-Mart he would have answered "no" !!! So I am going to read into it just a little and say that there is a good chance something is going on between the two companies!! jmo
GO SVFC!!!
Yep funny stuff! But in all seriousness SVFC does have what it takes to make it to the big boards and trade well over a few dollars!!! SVFC is a real company with a real product and a U.S. Patent with international patents to be granted any day!! If only there was a way to convince people how much real potential there is with SVFC !! Oh well I got my shares and will be adding more in two days!!! :)
Go SVFC !
LOL!! Me too! And I would just sit in it for a wile and take in the moment...
Go judge Oing
Go SVFC
Daddy wants a new pair of pants!!
Judge Oing orders IR to pay SVFC 10 million in damages and an additional 50 million in punitive damages!!!!
What would a pr like that do for the pps?
Just the thought of it gives me goose bumps!!!
Go Svfc
You my friend are a wise one!!
Go SVFC
It's going to happen!!!! SVFC will be trading well over a dollar at some point in the future!!! And I will still have several million shares!!!!
SVFC is the real deal!!!
I might take some of my SVFC profits and buy a house in the Caribbean. I have a feeling that one is about to go into default by an accredited investor
Can you say margin call?
Go Svfc
Millions of SVFC shares = millions of dollars!!!!
Millions I tell ya millions!!!!
Go SVFC
Hooooowwwwl
SVFC @ $100.00 a share would make me happy :) but I can honestly say in full disclosure that I will be selling some of my shares @ $75.00
With only 1.32 days to cover and news expected tomorrow I think it would be wise for the short interest to cover first thing in the morrning!!! Don't you?
IMO
Go SVFC !!! :)
SVFC and stem cell medicine is like something out of a si-fi movie!!! Go to the doctor with heart failure and in 30- 45 minuets be treated with you're own stem cells and no more heart failure!!!! If people can't see that SVFC will Change the way most of worlds medical problems are treated ( and cured ) maybe they should get a stem cell treatment for their vision!!!
The future has arrived!!
SVFC is the real deal
Intellicell Bioscien (SVFC)
0.0033 + 0.0001 (3.13%)
Volume: 12,671,838 @ 3:53:46 PM ET
Bid Ask Day's Range
0.0031 0.0035 0.003 - 0.0034
HOOOOOWWWWL :)
Well, well, well, what do ya know... SVFC had Another green day!!!!
7% here 3% there and all of a sudden SVFC is up 30% over the last six trading days!! And I'll bet SVFC will continue this up trend!! I do have to say that I feel a little sorry for those that sold and wish them the best luck on getting in before the next run, witch as I stated started six trading days ago.
But... It's not to late to catch the big move that will surely be coming very soon. How does a 300% day sound? Or how about a 600% week or a 2000% month?!!!! Stick around the greatest show on earth is about to start!!!!!
Go SVFC !!!
SVFC looking good here!!!!
SVFC should see some major action soon!!!
Short Squeeze
Definition of 'Short Squeeze'
A situation in which a heavily shorted stock or commodity moves sharply higher, forcing more short sellers to close out their short positions and adding to the upward pressure on the stock. A short squeeze implies that short sellers are being squeezed out of their short positions, usually at a loss. A short squeeze is generally triggered by a positive development that suggests the stock may be embarking on a turnaround. Although the turnaround in the stock’s fortunes may only prove to be temporary, few short sellers can afford to risk runaway losses on their short positions and may prefer to close them out even if it means taking a substantial loss.
Investopedia explains 'Short Squeeze'
If a stock starts to rise rapidly, the trend may continue to escalate because the short sellers will likely want out. For example, if a stock rises 15% in one day, those with short positions may be forced to liquidate and cover their position by purchasing the stock. If enough short sellers buy back the stock, the price is pushed even higher.
Two measures useful in identifying stocks at risk of a short squeeze are (a) short interest and (b) short-interest ratio. Short interest refers to the total number of shares sold short as a percentage of total shares outstanding, while short-interest ratio (SIR) is the total number of shares sold short divided by the stock’s average daily trading volume.
As an example, consider a hypothetical biotech company, Medico, that has a drug candidate in advanced clinical trials as a treatment for skin cancer. There is considerable skepticism among investors about whether this drug candidate will actually work, and as a result, 5 million Medico shares have been sold short of its 25 million shares outstanding. Short interest on Medico is therefore 20%, and with daily trading volume averaging 1 million shares, the SIR is 5. The SIR means that it would take 5 days for short sellers to buy back all Medico shares that have been sold short.
Assume that because of the huge short interest, Medico had declined from $15 a few months ago to $5 shortly before release of the clinical trial results. When the results are announced, they indicate that Medico’s drug candidate works better than expected as a treatment for skin cancer. Medico’s shares will “gap up” on the news, perhaps to $8 or higher, as speculators buy the stock and short sellers scramble to cover their short positions. A short squeeze in Medico is now on, and can drive it much higher due to massive buying pressure.
Contrarian investors look for stocks with heavy short interest specifically because of a short-squeeze risk. These investors may accumulate long positions in a heavily shorted stock if they believe its chances of success are significantly higher than believed by those who are bearish on it. The risk-reward payoff for a heavily shorted stock trading in the low single digits is quite favorable for contrarian investors with long positions. Their risk is limited to the price paid for it, while the profit potential is unlimited. This is diametrically opposite to the risk-reward profile of the short seller, who bears the risk of theoretically unlimited losses if the stock spikes higher on a short squeeze.
Looking forward to a great day!!!
Go SVFC :)
SVFC!!! It's Going to be a great week for SVFC longs!!!
SVFC!!! It's Going to be a great month for SVFC longs!!!
SVFC!!! It's Going to be a great year for SVFC longs!!!
And that means that the short interest won't be very happy, witch makes me very very happy and I like being happy!!!
Go Svfc!!!
Watch SVFC from the sidelines and wish you would of bought or buy SVFC and you're wishes will come true!!!